Transcription factor Snai1‑1 induces osteosarcoma invasion and metastasis by inhibiting E‑cadherin expression

Yang,Huiguang; Zhang,Yunqing; Zhou,Zhengming; Jiang,Xuefeng; Shen,Aidong

doi:10.3892/ol.2014.2079

Transcription factor Snai1‑1 induces osteosarcoma invasion and metastasis by inhibiting E‑cadherin expression

Authors:
- Huiguang Yang
- Yunqing Zhang
- Zhengming Zhou
- Xuefeng Jiang
- Aidong Shen
View Affiliations

Affiliations: Department of Orthopaedics, The Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin, Jiangsu 214400, P.R. China
Published online on: April 22, 2014 https://doi.org/10.3892/ol.2014.2079
Pages: 193-197

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma (OS) is a type of primary malignant bone tumor with a high propensity for local recurrence and distant metastasis. A previous study showed Snail‑1 is highly expressed in OS cells. The present study aimed to investigate the association between the transcription factor Snai1 and E‑cadherin in OS. SaOS2 OS cells were transfected either with a plasmid expressing short hairpin RNA (shRNA) specific for the Snai1‑1 gene (SaOS2‑shRNA) or a negative control plasmid (SaOS2‑Mock). The expression levels of E‑cadherin and Snai1‑1 in the transfected and control cells were determined by quantitative polymerase chain reaction and western blot analysis. In addition, the study was extended to evaluate the migratory and invasive properties of the cells through a Transwell experiment. The results show that E‑cadherin was expressed at a high level in the SaOS2‑shRNA cells, which were much less migratory and invasive than the control cells. Overexpression of Snai1‑1 in OS is associated with tumor progression, possibly through the suppression of E‑cadherin expression and induction of the process of epithelial‑mesenchymal transition, which contributes to the proceeding invasion and metastasis of OS cells.

View Figures

View References

1	Ferguson WS and Goorin AM: Current treatment of osteosarcoma. Cancer Invest. 19:292–315. 2001.
2	Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 115:1531–1543. 2009.
3	Nieto MA: The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol. 3:155–166. 2002.
4	Ferrari S, Smeland S, Mercuri M, et al; Italian and Scandinavian Sarcoma Groups. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 23:8845–8852. 2005.
5	Yang H, Zhang Y, Zhou Z, et al: Snail-1 regulates VDR signaling and inhibits 1,25(OH)-D₃ action in osteosarcoma. Eur J Pharmacol. 670:341–346. 2011.
6	Perez-Moreno M, Jamora C and Fuchs E: Sticky business: orchestrating cellular signals at adherens junctions. Cell. 112:535–548. 2003.
7	Takeichi M: Morphogenetic roles of classic cadherins. Curr Opin Cell Biol. 7:619–627. 1995.
8	Huber O, Bierkamp C and Kemler R: Cadherins and catenins in development. Curr Opin Cell Biol. 8:685–691. 1996.
9	De Wever O and Mareel M: Role of tissue stroma in cancer cell invasion. J Pathol. 200:429–447. 2003.
10	Vleminckx K, Vakaet L Jr, Mareel M, et al: Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell. 66:107–119. 1991.
11	Perl AK, Wilgenbus P, Dahl U, Semb H and Christofori G: A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 392:190–193. 1998.
12	Batlle E, Sancho E, Franci C, et al: The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2:84–89. 2000.
13	Kansara M and Thomas DM: Molecular pathogenesis of osteosarcoma. DNA Cell Biol. 26:1–18. 2007.
14	Tang N, Song WX, Luo J, et al: Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res. 466:2114–2130. 2008.
15	Meyers PA, Schwartz CL, Krailo MD, et al; Children’s Oncology Group. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children’s Oncology Group. J Clin Oncol. 26:633–638. 2008.
16	Kager L, Zoubek A, Potschger U, et al; Cooperative German-Austrian-Swiss Osteosarcoma Study Group. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 21:2011–2018. 2003.
17	Klymkowsky MW and Savagner P: Epithelial-mesenchymal transition: a cancer researcher’s conceptual friend and foe. Am J Pathol. 174:1588–1593. 2009.
18	Peinado H, Del Carmen Iglesias-de la Cruz M, Olmeda D, et al: A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression. EMBO J. 24:3446–3458. 2005.
19	Yang J, Mani SA, Donaher JL, et al: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 117:927–939. 2004.
20	Tlsty TD and Coussens LM: Tumor stroma and regulation of cancer development. Annu Rev Pathol. 1:119–150. 2006.
21	Yehiely F, Moyano JV, Evans JR, et al: Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med. 12:537–544. 2006.
22	Lacroix M, Toillon R and Leclercq G: Stable ‘portrait’ of breast tumors during progression: data from biology, pathology and genetics. Endocr Relat Cancer. 11:497–522. 2004.
23	Zhuang Z, Lininger RA, Man YG, et al: Identical clonality of both components of mammary carcinosarcoma with differential loss of heterozygosity. Mod Pathol. 10:354–362. 1997.
24	Berx G, Cleton-Jansen AM, Strumane K, et al: E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene. 13:1919–1925. 1996.
25	Castro Alves C, Rosivatz E, Schott C, et al: Slug is overexpressed in gastric carcinomas and may act synergistically with SIP1 and Snail in the down-regulation of E-cadherin. J Pathol. 211:507–515. 2007.
26	Saegusa M, Hashimura M, Kuwata T and Okayasu I: Requirement of the Akt/beta-catenin pathway for uterine carcinosarcoma genesis, modulating E-cadherin expression through the transactivation of slug. Am J Pathol. 174:2107–2115. 2009.
27	Moll R, Mitze M, Frixen UH and Birchmeier W: Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol. 143:1731–1742. 1993.
28	Côme C, Magnino F, Bibeau F, et al: Snail and slug play distinct roles during breast carcinoma progression. Clin Cancer Res. 12:5395–5402. 2006.
29	Peinado H, Ballestar E, Esteller M and Cano A: Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol. 24:306–319. 2004.
30	Peinado H, Olmeda D and Cano A: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007.
31	Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 7:131–142. 2006.
32	Barrallo-Gimeno A and Nieto MA: The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development. 132:3151–3161. 2005.
33	Martin TA, Goyal A, Watkins G and Jiang WG: Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol. 12:488–496. 2005.
34	Parker BS, Argani P, Cook BP, et al: Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res. 64:7857–7866. 2004.